{"product_id":"retatrutide-3d-20mg-uae","title":"Retatrutide 3D 20mg UAE: 20mg\/3ml Pen \u0026 Product","description":"\u003ch1\u003e\u003cstrong\u003e Retatrutide 3D 20mg UAE: Pre-Filled Pen \u0026amp; Product Guide\u003c\/strong\u003e\u003c\/h1\u003e\u003cp\u003eRetatrutide 3D 20mg UAE is a product listing featuring a pre-filled pen labeled 20mg\/3ml, with the packaging stating that one pen contains 5 doses. The box also carries the wording “For export only,” while the pen is labeled as a 20mg\/3ml solution.\u003c\/p\u003e\u003cp\u003eRetatrutide itself is an investigational compound also known as LY3437943. It is being studied as a triple receptor agonist involving the GIP, GLP-1 and glucagon pathways. Current clinical development has progressed into Phase 3 and Phase 3b studies, but retatrutide has not been approved for public use.\u003c\/p\u003e\u003cp\u003eFor UAE readers, the distinction between an online product listing and an authorized pharmaceutical medicine is especially important. The product packaging and online availability should therefore be considered separately from regulatory authorization.\u003c\/p\u003e\u003ch2\u003eQuick Product Overview\u003c\/h2\u003e\u003cp\u003eProduct Information\u003c\/p\u003e\u003cp\u003eDetails\u003c\/p\u003e\u003cp\u003eProduct\u003c\/p\u003e\u003cp\u003eRetatrutide 3D\u003c\/p\u003e\u003cp\u003eActive compound\u003c\/p\u003e\u003cp\u003eRetatrutide\u003c\/p\u003e\u003cp\u003eDevelopment code\u003c\/p\u003e\u003cp\u003eLY3437943\u003c\/p\u003e\u003cp\u003eListed strength\u003c\/p\u003e\u003cp\u003e20mg\u003c\/p\u003e\u003cp\u003eListed volume\u003c\/p\u003e\u003cp\u003e3ml\u003c\/p\u003e\u003cp\u003eFormat\u003c\/p\u003e\u003cp\u003ePre-filled pen\u003c\/p\u003e\u003cp\u003ePackaging statement\u003c\/p\u003e\u003cp\u003e1 pen contains 5 doses\u003c\/p\u003e\u003cp\u003eLabeling\u003c\/p\u003e\u003cp\u003eFor export only\u003c\/p\u003e\u003cp\u003ePen labeling\u003c\/p\u003e\u003cp\u003e20mg\/3ml solution\u003c\/p\u003e\u003cp\u003eScientific category\u003c\/p\u003e\u003cp\u003eInvestigational compound\u003c\/p\u003e\u003cp\u003eMarket context\u003c\/p\u003e\u003cp\u003eUAE \/ export-oriented listing\u003c\/p\u003e\u003cp\u003eThe product-specific details in this table are based on the supplied packaging image. Current batch, manufacturer, COA, storage and regulatory documentation should be verified separately.\u003c\/p\u003e\u003ch2\u003eWhat Is Retatrutide?\u003c\/h2\u003e\u003cp\u003eRetatrutide is an investigational molecule developed by Eli Lilly and identified in scientific and clinical-trial records by the code LY3437943.\u003c\/p\u003e\u003cp\u003eIts main scientific distinction is its activity across three receptor pathways:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eGLP-1\u003c\/li\u003e\n\u003cli\u003eGIP\u003c\/li\u003e\n\u003cli\u003eGlucagon\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eBecause it interacts with all three, retatrutide is commonly described as a triple agonist. This distinguishes it mechanistically from single-pathway and dual-pathway metabolic therapies.\u003c\/p\u003e\u003ch2\u003eUnderstanding the 20mg\/3ml Pen\u003c\/h2\u003e\u003cp\u003eThe supplied packaging identifies this presentation as:\u003c\/p\u003e\u003cp\u003e20mg \/ 3ml\u003c\/p\u003e\u003cp\u003eand states:\u003c\/p\u003e\u003cp\u003e1 pen contains 5 doses\u003c\/p\u003e\u003cp\u003eThe pen itself is labeled as a 20mg\/3ml solution.\u003c\/p\u003e\u003cp\u003eThese statements describe the product's packaging and format. They should not be interpreted as a recommendation for how the product should be administered.\u003c\/p\u003e\u003cp\u003eDifferent retatrutide listings can vary in strength, volume, pen design and documentation. Current UAE-focused supplier pages, for example, list pen presentations ranging from 10mg through 60mg.\u003c\/p\u003e\u003ch2\u003eRetatrutide and the Triple-Receptor Concept\u003c\/h2\u003e\u003cp\u003eThe scientific interest in retatrutide is closely related to its multi-receptor design.\u003c\/p\u003e\u003ch3\u003eGLP-1 Pathway\u003c\/h3\u003e\u003cp\u003eGLP-1 signaling is associated with appetite regulation, satiety and glucose-related physiological processes.\u003c\/p\u003e\u003ch3\u003eGIP Pathway\u003c\/h3\u003e\u003cp\u003eGIP participates in glucose-dependent signaling and metabolic physiology.\u003c\/p\u003e\u003ch3\u003eGlucagon Pathway\u003c\/h3\u003e\u003cp\u003eGlucagon contributes to energy metabolism and regulation of stored energy.\u003c\/p\u003e\u003cp\u003eResearchers are investigating whether activity across these three pathways can produce useful metabolic effects in controlled clinical studies.\u003c\/p\u003e\u003cp\u003eThe mechanism is a description of the investigational compound; it does not establish a particular outcome for an individual product.\u003c\/p\u003e\u003ch2\u003eRetatrutide Clinical Development\u003c\/h2\u003e\u003cp\u003eRetatrutide has progressed into a large clinical-development program.\u003c\/p\u003e\u003cp\u003eCurrent clinical studies include Phase 3 and Phase 3b investigations involving obesity and related metabolic conditions. ClinicalTrials.gov records include studies evaluating weight reduction, maintenance of weight reduction, safety, dose-escalation strategies and comparisons with other therapies.\u003c\/p\u003e\u003cp\u003eThis later-stage development is an important milestone, but clinical-trial progress should not be confused with regulatory approval.\u003c\/p\u003e\u003ch2\u003e Retatrutide 3D 20mg UAE\u003cimg class=\"_resizableImage_1wqvo_111\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0745\/6315\/8104\/files\/z32sDrON9WxVbfUXtR6AMUGe2Nv1JLU3TgHZOHkn.png?v=1788096300\"\u003e and Weight-Management Studies\u003c\/h2\u003e\u003cp\u003eWeight reduction is one of the main areas being investigated in retatrutide clinical development.\u003c\/p\u003e\u003cp\u003eEarlier Phase 2 research reported substantial average body-weight changes over 48 weeks, while later Phase 3 programs have evaluated longer follow-up and different patient populations.\u003c\/p\u003e\u003cp\u003eWhen reading weight-related clinical findings, it is important to consider:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eStudy population\u003c\/li\u003e\n\u003cli\u003eDuration\u003c\/li\u003e\n\u003cli\u003eComparator\u003c\/li\u003e\n\u003cli\u003eStudied dose\u003c\/li\u003e\n\u003cli\u003ePrimary endpoints\u003c\/li\u003e\n\u003cli\u003eSafety findings\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eGroup-level clinical results do not guarantee a particular outcome for an individual.\u003c\/p\u003e\u003ch2\u003e Retatrutide 3D 20mg UAE Product Presentation\u003c\/h2\u003e\u003cp\u003eThe Retatrutide 3D 20mg UAE packaging supplied for this page shows a clean pre-filled pen presentation with:\u003c\/p\u003e\u003cp\u003eRETATRUTIDE 3D\u003c\/p\u003e\u003cp\u003e20mg\/3ml\u003c\/p\u003e\u003cp\u003e1 pen contains 5 doses\u003c\/p\u003e\u003cp\u003eThe package also includes the statement:\u003c\/p\u003e\u003cp\u003eFor export only\u003c\/p\u003e\u003cp\u003eThese visible identifiers can be useful for product cataloging and differentiation from other strengths.\u003c\/p\u003e\u003cp\u003eAt the same time, packaging text does not by itself establish authenticity, purity, sterility, clinical effectiveness or regulatory authorization.\u003c\/p\u003e\u003ch2\u003eWhy Exact Product Identification Matters\u003c\/h2\u003e\u003cp\u003eRetatrutide products can be offered in different forms and strengths.\u003c\/p\u003e\u003cp\u003eCurrent UAE-facing research listings show multiple pen and vial options, including 20mg, 30mg, 40mg, 50mg and 60mg presentations.\u003c\/p\u003e\u003cp\u003eFor that reason, a product page should clearly distinguish:\u003c\/p\u003e\u003ch3\u003eStrength\u003c\/h3\u003e\u003cp\u003eVerify the stated milligram amount.\u003c\/p\u003e\u003ch3\u003eVolume\u003c\/h3\u003e\u003cp\u003eCheck the listed total volume.\u003c\/p\u003e\u003ch3\u003eFormat\u003c\/h3\u003e\u003cp\u003eIdentify whether the presentation is a pen or vial.\u003c\/p\u003e\u003ch3\u003eBatch\u003c\/h3\u003e\u003cp\u003eLook for a lot or batch reference.\u003c\/p\u003e\u003ch3\u003eDocumentation\u003c\/h3\u003e\u003cp\u003eReview any available COA or laboratory records.\u003c\/p\u003e\u003ch3\u003eIntended use\u003c\/h3\u003e\u003cp\u003eConfirm the product's declared research or regulatory category.\u003c\/p\u003e\u003ch2\u003eProduct Verification and Laboratory Documentation\u003c\/h2\u003e\u003cp\u003eFor investigational compounds, documentation can be as important as the product name.\u003c\/p\u003e\u003ch3\u003eCertificate of Analysis\u003c\/h3\u003e\u003cp\u003eA batch-specific COA can connect analytical findings to a specific lot.\u003c\/p\u003e\u003ch3\u003ePurity Testing\u003c\/h3\u003e\u003cp\u003eSome UAE research suppliers publish HPLC-based purity information or independent testing records.\u003c\/p\u003e\u003ch3\u003eIdentity Testing\u003c\/h3\u003e\u003cp\u003eLaboratory methods can provide evidence about the identity of the material.\u003c\/p\u003e\u003ch3\u003eBatch Traceability\u003c\/h3\u003e\u003cp\u003eA unique batch number can make documentation easier to verify.\u003c\/p\u003e\u003ch3\u003eSupplier Information\u003c\/h3\u003e\u003cp\u003eThe supplier or manufacturer should be clearly identified where applicable.\u003c\/p\u003e\u003cp\u003eA documentation package does not itself establish approval for human use, but it can improve transparency and traceability.\u003c\/p\u003e\u003ch2\u003eRetatrutide 3D 20mg UAE and Regulatory Considerations\u003c\/h2\u003e\u003cp\u003eThe UAE regulatory position should be clearly separated from product marketing.\u003c\/p\u003e\u003cp\u003eThe Abu Dhabi Department of Health issued Circular No. 40\/2026 on March 6, 2026, warning healthcare facilities, professionals and the public against unauthorized retatrutide products. The circular states that retatrutide remained under clinical development and that unauthorized products were not licensed or authorized for use or distribution.\u003c\/p\u003e\u003cp\u003eThis is especially relevant when evaluating online product pages.\u003c\/p\u003e\u003ch3\u003eImportant distinction\u003c\/h3\u003e\u003cp\u003eOnline listing ≠ regulatory approval\u003c\/p\u003e\u003cp\u003eClinical development ≠ public authorization\u003c\/p\u003e\u003cp\u003ePackaging label ≠ proof of authenticity\u003c\/p\u003e\u003cp\u003eListed price ≠ official medicine price\u003c\/p\u003e\u003cp\u003eA professional product page should avoid implying otherwise.\u003c\/p\u003e\u003ch2\u003eHow to Evaluate a Retatrutide Pen\u003c\/h2\u003e\u003cp\u003eBefore relying on a product listing, check:\u003c\/p\u003e\u003ch3\u003eProduct name and strength\u003c\/h3\u003e\u003cp\u003eConfirm that the label matches the listing.\u003c\/p\u003e\u003ch3\u003eVolume\u003c\/h3\u003e\u003cp\u003eVerify the total stated volume.\u003c\/p\u003e\u003ch3\u003eBatch details\u003c\/h3\u003e\u003cp\u003eLook for lot identification.\u003c\/p\u003e\u003ch3\u003eTesting documents\u003c\/h3\u003e\u003cp\u003eReview available laboratory and COA information.\u003c\/p\u003e\u003ch3\u003eSupplier identity\u003c\/h3\u003e\u003cp\u003eConfirm who is responsible for the product.\u003c\/p\u003e\u003ch3\u003eCurrent UAE status\u003c\/h3\u003e\u003cp\u003eCheck official UAE health-authority information rather than relying solely on seller claims.\u003c\/p\u003e\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\u003ch3\u003eWhat is Retatrutide 3D 20mg UAE?\u003c\/h3\u003e\u003cp\u003eIt is a product presentation labeled RETATRUTIDE 3D 20mg\/3ml and shown in the supplied image as a pre-filled pen.\u003c\/p\u003e\u003ch3\u003eHow much does the package contain?\u003c\/h3\u003e\u003cp\u003eThe supplied packaging states 20mg\/3ml.\u003c\/p\u003e\u003ch3\u003eHow many doses does one pen contain?\u003c\/h3\u003e\u003cp\u003eThe box states that 1 pen contains 5 doses.\u003c\/p\u003e\u003ch3\u003eWhat is LY3437943?\u003c\/h3\u003e\u003cp\u003eLY3437943 is the development code associated with retatrutide.\u003c\/p\u003e\u003ch3\u003eWhy is retatrutide called a triple agonist?\u003c\/h3\u003e\u003cp\u003eBecause it is being investigated across GIP, GLP-1 and glucagon receptor pathways.\u003c\/p\u003e\u003ch3\u003eIs retatrutide approved in the UAE?\u003c\/h3\u003e\u003cp\u003eThe Abu Dhabi Department of Health issued a March 2026 warning describing retatrutide as an unauthorized medical product and stating that it remained under clinical development.\u003c\/p\u003e\u003ch3\u003eDoes the packaging prove product authenticity?\u003c\/h3\u003e\u003cp\u003eNo. Packaging alone does not establish authenticity, purity, sterility, safety or regulatory authorization.\u003c\/p\u003e\u003ch3\u003eWhat should be checked before evaluating the product?\u003c\/h3\u003e\u003cp\u003eCheck the exact label, strength, volume, batch information, laboratory documents, COA and current regulatory status.\u003c\/p\u003e\u003ch2\u003eConclusion\u003c\/h2\u003e\u003cp\u003eRetatrutide 3D 20mg UAE is a pre-filled pen presentation identified on the supplied packaging as 20mg\/3ml, with the package stating that one pen contains five doses.\u003c\/p\u003e\u003cp\u003eRetatrutide itself is an investigational triple receptor agonist involving GIP, GLP-1 and glucagon pathways and is currently being evaluated through a broad clinical-development program.\u003c\/p\u003e\u003cp\u003eFor UAE readers, regulatory context is particularly important. The Abu Dhabi Department of Health has warned against unauthorized retatrutide products and stated that the compound remains under clinical development.\u003c\/p\u003e\u003cp\u003eA well-structured product page should therefore provide accurate identification, clear specifications, transparent documentation and appropriate regulatory language.\u003c\/p\u003e\u003ch2\u003eResearch \u0026amp; Regulatory Disclaimer\u003c\/h2\u003e\u003cp\u003eThis page is provided for educational and product-identification purposes only. It does not provide individualized medical advice, dosing instructions, injection protocols or treatment recommendations.\u003c\/p\u003e\u003cp\u003eRetatrutide remains investigational and is not currently approved for public use. Online availability does not establish regulatory authorization, authenticity, purity, safety or suitability for personal treatment. Always verify current UAE regulatory information and official product documentation.\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e","brand":"Pharma Testostrone","offers":[{"title":"Default Title","offer_id":44629829255256,"sku":null,"price":1050.0,"currency_code":"AED","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0745\/6315\/8104\/files\/Retatrutide_3D_20mg_UAE_3ml_pre-filled_pen.jpg?v=1788095921","url":"https:\/\/timewell.store\/products\/retatrutide-3d-20mg-uae","provider":"Timewell","version":"1.0","type":"link"}